 <h1>Elzonris Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>tagraxofusp</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about tagraxofusp. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Elzonris.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to tagraxofusp: intravenous solution</i></p><h3>Warning</h3><p class="blackboxWarning-title">Intravenous route (Solution)</p><p>Capillary Leak Syndrome (CLS) which may be life-threatening or fatal, can occur in patients receiving tagraxofusp-erzs. Monitor for signs and symptoms of CLS and take actions as recommended</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, tagraxofusp (the active ingredient contained in Elzonris) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking tagraxofusp:</p><p>
<i>More common</i>
</p><ul>
<li>Black, tarry stools</li>
<li>bloating or swelling of the face, arms, hands, lower legs, or feet</li>
<li>bloody or cloudy urine</li>
<li>blurred vision</li>
<li>chills</li>
<li>confusion</li>
<li>cough</li>
<li>decrease or increase in the amount of urine</li>
<li>dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position</li>
<li>fast, pounding, or irregular heartbeat or pulse</li>
<li>fever</li>
<li>headache</li>
<li>itching skin</li>
<li>lower back or side pain</li>
<li>nausea</li>
<li>nervousness</li>
<li>nosebleed</li>
<li>painful or difficult urination</li>
<li>pale skin</li>
<li>pounding in the ears</li>
<li>rapid weight gain</li>
<li>slow heartbeat</li>
<li>small red or purple spots on the skin</li>
<li>sore throat</li>
<li>stomach pain</li>
<li>sweating</li>
<li>tightness in the chest</li>
<li>tingling of the hands or feet</li>
<li>troubled breathing</li>
<li>ulcers, sores, or white spots in the mouth</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
<li>unusual weight gain or loss</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of tagraxofusp may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Anxiety</li>
<li>arm, back, or leg pain</li>
<li>constipation</li>
<li>decreased appetite</li>
<li>diarrhea</li>
<li>mouth or throat pain</li>
<li>nausea</li>
<li>trouble sleeping</li>
<li>vomiting</li>
</ul><p>
<!-- end intravenous solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to tagraxofusp: intravenous solution</i></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Decreased platelets (67%), decreased hemoglobin (60%), decreased neutrophils (37%)<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Very common</b> (10% or more): Hypersensitivity (46%)<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Frequency not reported</b>: Immunogenicity<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Increased glucose (67%), decreased calcium (57%), decreased sodium (50%), decreased potassium (39%), decreased phosphate (30%), increased alkaline phosphatase (26%), decreased appetite (24%), increased potassium (21%), decreased magnesium (14%), decreased glucose (11%), increased sodium (10%)<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Insomnia (17%), anxiety (15%), confusion (11%)<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Elevated liver enzymes (Grade 1 or 2 in 48%, Grade 3 in 36%, Grade 4 in 4%) (88%), ALT increase (82%), AST increase (79%)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Dyspnea (19%), cough (14%), epistaxis (14%), oropharyngeal pain (12%)<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (45%), peripheral edema (43%), pyrexia (43%), weight increase (31%), chills (29%)<sup>[Ref]</sup></p><h3>General</h3><p>-The most common laboratory abnormalities (incidence 50% or greater) are decreases in albumin, platelets, hemoglobin, calcium, and sodium and increases in glucose, ALT, and AST.</p>
<p>-The most common adverse reactions (incidence 30% or greater) are capillary leak syndrome (CSL), nausea, fatigue, peripheral edema, pyrexia, and weight increase.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (29%), dizziness (20%)<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Hematuria (10%), decreased creatinine (27%)<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Capillary leak syndrome (55%), hypotension (29%), tachycardia (17%), hypertension (15%)<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Petechiae (10%), pruritus (10%)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (49%), constipation (23%), vomiting (21%), diarrhea (20%)<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY. </p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>What disease is Elzonris (tagraxofusp-erzs) used to treat?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about Elzonris (tagraxofusp)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: miscellaneous antineoplastics</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Elzonris &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to tagraxofusp: intravenous solution</i></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Decreased platelets (67%), decreased hemoglobin (60%), decreased neutrophils (37%)<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Very common</b> (10% or more): Hypersensitivity (46%)<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Frequency not reported</b>: Immunogenicity<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Increased glucose (67%), decreased calcium (57%), decreased sodium (50%), decreased potassium (39%), decreased phosphate (30%), increased alkaline phosphatase (26%), decreased appetite (24%), increased potassium (21%), decreased magnesium (14%), decreased glucose (11%), increased sodium (10%)<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Insomnia (17%), anxiety (15%), confusion (11%)<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Elevated liver enzymes (Grade 1 or 2 in 48%, Grade 3 in 36%, Grade 4 in 4%) (88%), ALT increase (82%), AST increase (79%)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Dyspnea (19%), cough (14%), epistaxis (14%), oropharyngeal pain (12%)<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (45%), peripheral edema (43%), pyrexia (43%), weight increase (31%), chills (29%)<sup>[Ref]</sup></p><h3>General</h3><p>-The most common laboratory abnormalities (incidence 50% or greater) are decreases in albumin, platelets, hemoglobin, calcium, and sodium and increases in glucose, ALT, and AST.</p><p>-The most common adverse reactions (incidence 30% or greater) are capillary leak syndrome (CSL), nausea, fatigue, peripheral edema, pyrexia, and weight increase.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (29%), dizziness (20%)<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Hematuria (10%), decreased creatinine (27%)<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Capillary leak syndrome (55%), hypotension (29%), tachycardia (17%), hypertension (15%)<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Petechiae (10%), pruritus (10%)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (49%), constipation (23%), vomiting (21%), diarrhea (20%)<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY. </p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>What disease is Elzonris (tagraxofusp-erzs) used to treat?</li>
</ul><h2>More about Elzonris (tagraxofusp)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: miscellaneous antineoplastics</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Elzonris &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>